agenus

NEWS RELEASE

Agenus to Present Expanded Outcomes Analysis of BOT+BAL Across Historically Immunotherapy-Resistant Solid Tumors at ESMO Asia Congress 2026

2026-11-29

- Oral presentation to examine depth and durability of response and long-term survival across five tumor types, including extended follow-up in select cohorts

LEXINGTON, Mass.--(BUSINESS WIRE)-- **Agenus** Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that an expanded analysis from its large Phase 1b clinical trial of more than 400 patients with advanced solid tumors evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, will be featured in a rapid oral presentation at the European Society for Medical Oncology (ESMO) Asia Congress being held in Singapore from December 4-6, 2026.

Building on the pan-tumor findings previously presented at ESMO 2025, the oral presentation will provide a more detailed examination of clinical outcomes across five tumor types, including microsatellite-stable metastatic colorectal cancer without active liver metastases, sarcomas, ovarian cancer, and non-small cell lung cancer and hepatocellular carcinoma resistant or refractory to prior immunotherapy.

The analysis will examine the depth and durability of response, long-term survival and safety, including additional follow-up in select tumor cohorts.

These findings are part of Agenus' broader clinical program investigating the potential of BOT+BAL to extend the benefits of immunotherapy to patients with cancers that historically have been difficult to treat with conventional immunotherapies.

Presentation Details

Title: Broad clinical activity of next-generation anti–CTLA-4 (botensilimab) plus anti–PD-1 (balstilimab) across historically immunotherapy-resistant solid tumors
Presenter: Apostolia Maria Tsimberidou, MD, PhD, MBA, FASCO, FAAAS of the University of Texas, MD Anderson Cancer Center, Houston, US
Session: Developmental therapeutics and precision medicine
Session Date & Time: December 6, 2026, from 10:45 a.m. - 12:05 p.m. SGT | December 5, 9:45–11:05 p.m. EST
Presentation Date & Time: December 6, 2026, from 10:55 - 11:00 a.m. SGT | December 5, 9:55–10:00 p.m. EST
Location: Hall 407, Suntec Singapore
Presentation Number: 242RO

About Agenus

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit **www.agenusbio.com** or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Agenus' Commitment to Patient Access

Agenus is committed to expanding patient access to BOT+BAL through regulatory approvals, clinical trials and authorized early-access pathways. Following the first marketing authorizations for Botvymo® (botensilimab) and Evamplix® (balstilimab) in Armenia for eligible adults with microsatellite stable (MSS) metastatic colorectal cancer without active liver metastases who have previously received available standard therapies, BOT+BAL remains investigational outside Armenia and is not approved by the U.S. Food and Drug Administration (FDA).

In France, the national Autorisation d'Accès Compassionnel (AAC) program provides fully reimbursed, hospital-based access to BOT+BAL for eligible patients with MSS metastatic colorectal cancer without active liver metastases, platinum-resistant or platinum-refractory ovarian cancer, and certain advanced soft-tissue sarcomas. In a growing number of other countries, BOT+BAL is available through physician-initiated named-patient programs under local regulations. BAP Pharma serves as Agenus' global partner for the French AAC pathway and named-patient access programs.

Physicians seeking information about authorized access pathways can visit the Patient Access section of the Agenus website.

About Botensilimab (BOT)

Botensilimab (BOT) is a human multifunctional, Fc-enhanced anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. BOT augments immune responses across a wide range of tumor types by priming and activating T cells, reducing intratumoral regulatory T cells, activating myeloid cells and inducing durable memory responses.

Approximately 1,500 patients have been treated with BOT and balstilimab (BAL) in phase 1 and phase 2 clinical trials. The combination with Agenus’ investigational PD-1 antibody, BAL, has shown clinical responses across more than nine cancers. For more information about BOT trials, visit **www.clinicaltrials.gov**.

About Balstilimab (BAL)

Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

Investors

917-362-1370 | **investor@agenusbio.com**

Media

781-674-4422 | **communications@agenusbio.com**

Source: Agenus Inc.